Based on its analysis of a large cohort of individuals homozygous for the ε4 variant of apolipoprotein E (APOE4), a multinational team of researchers is arguing that homozygosity for APOE4 should be considered a genetic form of Alzheimer’s disease. However, not everyone agrees that the findings warrant reclassifying APOE from risk factor to causal gene. Currently, APOE4 is classified as the strongest risk factor for developing AD. Another variant, the APOE2 variant, is protective, while APOE3 is neutral.

“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that has gained the backing of an impressive group of investors in a recently closed $100 million series A round.

Researchers from Peptidream Inc. presented preclinical characterization of novel carbonic anhydrase IX (CAIX)-targeting radiopeptides, [64Cu]PD-32766 and [177Lu]PD-32766, being developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC), respectively.

There is a compelling need to produce new antibiotics that hamper severe opportunistic infections, especially in immunocompromised individuals, such as those caused by gram-negative Pseudomonas aeruginosa.

Chemokine CXCL5 is an inflammatory mediator and a powerful neutrophil chemoattractant, which mainly acts through CXCR2 to produce its biological effects.

Amicetin-inspired inhibitors of the P-site (AIIPS), also known as CZ-02s, are a series of molecules that target and inhibit a unique site of the bacterial ribosome.